secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2026-09-08T20:10:14+00:00
Accession:  0001213900-26-098042
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar enters quiet period ahead of Phase 2b REZOLVE-AA follow-up data
----------------------------------------------------------------------

- Quiet period begins September 8, 2026 until 24-week off-treatment follow-up data from Phase 2b REZOLVE-AA study is announced.
- Study evaluates rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.
- Quiet period is consistent with prior quiet periods for Phase 2b REZOLVE studies and planned data disclosures.
- No financial or operational results disclosed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/0001213900-26-098042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/ea0304798-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-098042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer